# Cabazitaxel

Source: https://nuclide.cc/drugs/cabazitaxel/  
Nuclide record `cabazitaxel` (Agent). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A second taxane that works after docetaxel and beat a second hormone pill head-to-head (CARD).

## Summary

Cabazitaxel is a taxane with low affinity for the P-glycoprotein efflux pump, so it remains active in docetaxel-resistant disease. It is used in metastatic castration-resistant prostate cancer after docetaxel, with neutropenia as its main toxicity. TROPIC (2010) showed an overall survival benefit after docetaxel, and CARD (2019) showed it was superior to switching to a second androgen receptor pathway inhibitor in men who had already had one ARPI and docetaxel. It served as the comparator in TheraP, where it lost to 177Lu-PSMA-617 on PSA50 response (66% versus 37%) although overall survival was similar (HR 0.97), and in XALute against the T-cell engager xaluritamig. Its place relative to radioligands and T-cell engagers is therefore still being worked out. For a newcomer, it is the second taxane that works after docetaxel and beat a second hormone pill head-to-head.

## Fields

- Kind: Agent
- Status: approved
- Last checked: 2026-09-06
- Brand: Jevtana
- Modality: Cytotoxic chemotherapy (taxane)
- Mechanism: Taxane with low P-glycoprotein affinity, active in docetaxel-resistant disease.
- Approvals: US 2010: mCRPC after docetaxel

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Cabazitaxel
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cabazitaxel

## Connected records

- isotopes: [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- indications: [Metastatic castration-resistant prostate cancer](https://nuclide.cc/indications/prostate-mcrpc/), [Neuroendocrine and small-cell prostate cancer](https://nuclide.cc/indications/prostate-nepc/), [Prostate cancer](https://nuclide.cc/indications/prostate/)
- trials: [AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)](https://nuclide.cc/trials/nct07611110/), [TheraP (ANZUP 1603)](https://nuclide.cc/trials/therap/)
- key papers: [TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer](https://nuclide.cc/key-papers/paper-therap-lancet-2021/)

---
JSON: https://nuclide.cc/api/v1/entities/cabazitaxel.json